Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899847 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00899847: Completed Phase 2 study, sponsored by Stanford University.
NCT00899847 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899847, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
Primary Outcome
To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Filgrastim
- PROCEDURE Autologous peripheral blood stem cells (auto-PBSC) transplantation
- PROCEDURE Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT00899847 record still lists
NCT00899847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00899847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899847 about?
NCT00899847 is a clinical study titled "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG". To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
What is the current status of trial NCT00899847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00899847?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Filgrastim (DRUG), Autologous peripheral blood stem cells (auto-PBSC) transplantation (PROCEDURE), Allogeneic peripheral blood stem cells (allo-PBSC) transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00899847?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00899847's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia